title: The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer.
abstract: Survival from pancreatic cancer remains poor. Conventional treatment has resulted in only marginal improvements in survival compared with survival in the previous several decades. Thus, considerable interest has emerged regarding the potential use of common pharmaceutical agents as chemopreventative and chemotherapeutic options. Aspirin, metformin, statins, β-blockers, and bisphosphonates have biologically plausible mechanisms to inhibit pancreatic neoplasia, whereas dipeptidyl-peptidase 4 inhibitors may promote it. Regardless, real-world epidemiological data remain inconclusive. This review examines the hypotheses, evidence, and current state of the literature for each of these medications and their potential roles in the prevention and treatment of pancreatic cancer.
authors: Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
authors: Sunil
authors: S
authors: Amin
authors: Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
authors: Paolo
authors: P
authors: Boffetta
authors: Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
authors: Aimee L
authors: AL
authors: Lucas
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D058492:Drug Repositioning; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008687:Metformin / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000517:prevention & control*
chemical_list: D000319:Adrenergic beta-Antagonists; D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D054873:Dipeptidyl-Peptidase IV Inhibitors; D004164:Diphosphonates; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D008687:Metformin; D001241:Aspirin
keywords: Adenocarcinoma; Aspirin; Betablockers; Bisphosphonates; Dipeptidyl-peptidase 4 inhibitors; Epidemiology; Malignancy; Metformin; Pancreas; Statins